split-banner-image

OlympiA

Closed

ANZ 1404/BIG 6-13/AstraZeneca D081CC00006: OlympiA

BCT Study Chair:

Kelly-Anne Phillips

A randomized, double blind, parallel group, placebo-controlled multi-center phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA 1/2 mutations and high risk HER2-negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

international

1776

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

60

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

15

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

OLYMPIA PUBLICATIONS

2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.

Garber JE, Cameron D, Campbell C, Yothers G, Taboada M, El-Abed S, Rastogi P, McConnell R, Correa A, Delaloge S, Liu WT, Sharma P, Bergh J, Janni W, Balmana J, Loman N, Spanic T, Friedman S, Freeman T, Armstrong A, Korde L, Im S, Sagara Y, Viale G, Bliss J, Gianni L, Johannsson O, Zoppoli G, Martinez De Duenas E, Marme F, Fein L, Arnedos M, Ford J, Schmutzler R, Loibl S, Linderholm B, Lakhani SR, Gnant M, Gelmon K, Domchek SM, Sunkus E, Eisen A, Jager A, Piccart M, Phillips KA, et al. Annals of Oncology. 2026; DOI: 10.1016/j.annonc.2026.08.002, Article in press. Pub online 24 August 2026, E-pub

Systemic Therapy Management Strategies for Early-Stage Breast Cancer in Australia.

Zdenkowski N, Dear R, Kumar S, Martin H, Sabanathan D, Luen SJ, Yeo B. Asia-Pacific Journal of Clinical Oncology. 2026; 1-13, https://doi.org/10.1111/ajco.70123, E-pub

2024

OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: longerterm follow

Garber, J. SABCS 2024; GS1-09, Abstract

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer.

Ganz PA, Bandos H, Spanic T, Friedman S, Muller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Duenas E-M, Armstrong A, Im S-A, Song C, Zheng H, Sarsiek T, Sharma P, Geng C, Fu P, Rhiem K, Frachiger-Heuer H, Wimberger P, d’Kind de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugere C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, et al. Journal of Clinical Oncology. 2024; 42(11):1288-1300, DOI https://doi.org/10.1200/JCO.23.01214, E-pub

2023

Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BCRA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.

Yamauchi H, Toi M, Takayama S, Nakamura S, Takano T, Cui K, Campbell C, De Vos L, Geyer Jr C, Tutt A. Breast Cancer. 2023; 30596-605, https://doi.org/10.1007/s12282-023-01451-8, E-pub

2022

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

Geyer CE, Garber JE, Gelber RD, Yothers et al. and the OlympiA Clinical Trial Steering Committee and Investigators. Annals of Oncology. 2022; 33(12):1250 – 1268, Journal

LOAD MORE

Institutions